Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel Free ORGO Stock Alerts

Organogenesis (ORGO) Financials

Organogenesis logo
$1.21 -0.02 (-1.63%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$1.20 0.00 (-0.41%)
As of 07:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Organogenesis

Annual Income Statements for Organogenesis

This table shows Organogenesis' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -8.81 -65 -39 0.00 94 16 4.95 -0.94 20
Consolidated Net Income / (Loss)		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Net Income / (Loss) Continuing Operations		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Total Pre-Tax Income 		-15 -15 -65 -39 18 63 20 10 -2.81 47
Total Operating Income		 -8.78 -5.49 -52 -30 27 72 22 13 -1.28 45
Total Gross Profit		 91 137 125 185 251 353 346 327 366 427
Total Revenue		 139 199 193 261 338 467 451 433 482 564
Operating Revenue		 139 199 193 261 338 467 451 433 482 564
Total Cost of Revenue		 48 61 69 76 87 114 105 106 116 138
Operating Cost of Revenue		 48 61 69 76 87 114 105 106 116 138
Total Operating Expenses		 99 143 176 215 224 281 324 314 368 382
Selling, General & Admin Expense		 93 134 162 200 204 250 284 270 295 326
Research & Development Expense		 6.28 9.07 11 15 20 31 40 44 50 45
Other Operating Expenses / (Income)		 0.00 - 3.49 - - - 0.00 0.00 3.96 0.00
Impairment Charge		 - - - - - - 0.00 0.00 19 11
Total Other Income / (Expense), net		 -5.93 -9.06 -13 -8.71 -8.94 -9.13 -2.02 -2.13 -1.52 2.28
Interest Expense		 5.63 8.01 13 11 11 9.12 2.01 2.19 1.54 -2.28
Other Income / (Expense), net		 -0.45 -1.05 -0.31 2.15 2.34 -0.01 -0.01 0.06 0.02 -0.01
Income Tax Expense		 0.07 -7.03 0.08 0.15 0.53 -31 4.75 5.45 -3.67 9.94
Preferred Stock Dividends Declared		 - - 0.00 0.57 0.00 - 0.00 0.00 1.80 11
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.42 - - - - - 0.00 0.00 5.64
Basic Earnings per Share		 ($0.27) ($0.14) ($0.94) ($0.42) $0.16 $0.73 $0.12 $0.04 ($0.01) $0.16
Weighted Average Basic Shares Outstanding		 63.20M 63.88M 69.32M 92.84M 107.74M 128.33M 130.07M 131.23M 131.67M 126.74M
Diluted Earnings per Share		 ($0.27) ($0.14) ($0.94) ($0.42) $0.15 $0.70 $0.12 $0.04 ($0.01) $0.15
Weighted Average Diluted Shares Outstanding		 63.20M 63.88M 69.32M 92.84M 111.36M 133.66M 132.38M 132.75M 131.67M 130.25M
Weighted Average Basic & Diluted Shares Outstanding		 63.20M 63.88M 69.32M 92.84M 127.99M 128.77M 131.18M 131.96M 126.83M 128.64M

Quarterly Income Statements for Organogenesis

This table shows Organogenesis' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.57 -2.10 -17 12 5.88 -22 -12 15 39 -56 -99
Consolidated Net Income / (Loss)		 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53 -96
Net Income / (Loss) Continuing Operations		 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53 -96
Total Pre-Tax Income 		-1.80 -4.34 -15 5.82 10 -26 -12 21 63 -68 -51
Total Operating Income		 -1.27 -3.85 -14 6.24 10 -27 -13 21 63 -69 -51
Total Gross Profit		 72 81 101 88 96 63 73 115 176 11 20
Total Revenue		 100 110 130 115 127 87 101 151 226 37 44
Operating Revenue		 100 110 130 115 127 87 101 151 226 37 44
Total Cost of Revenue		 28 29 29 27 31 24 28 36 50 26 24
Operating Cost of Revenue		 28 29 29 27 31 24 28 36 50 26 24
Total Operating Expenses		 73 85 115 82 85 90 86 94 112 80 71
Selling, General & Admin Expense		 61 72 77 72 74 73 74 80 100 65 54
Research & Development Expense		 12 13 16 10 12 11 10 13 10 15 18
Other Operating Expenses / (Income)		 - - 3.96 0.00 - - 1.75 0.00 - - -1.19
Total Other Income / (Expense), net		 -0.53 -0.49 -0.65 -0.42 0.03 0.96 0.74 0.43 0.14 0.42 0.11
Interest Expense		 0.50 0.51 0.62 0.47 -0.06 -0.96 -0.67 -0.42 -0.24 -0.38 -0.14
Other Income / (Expense), net		 -0.03 0.02 -0.03 0.05 -0.03 0.00 0.07 0.02 -0.10 0.04 -0.03
Income Tax Expense		 -1.23 -2.24 2.50 -6.51 2.58 -6.94 -2.44 -0.41 20 -15 45
Preferred Stock Dividends Declared		 - 0.00 0.00 0.00 - 2.75 2.81 2.87 2.94 3.00 3.07
Basic Earnings per Share		 - ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.32 ($0.44) ($0.77)
Weighted Average Basic Shares Outstanding		 131.23M 131.86M 132.57M 132.58M 131.67M 126.30M 126.85M 126.88M 126.74M 127.80M 128.67M
Diluted Earnings per Share		 - ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.31 ($0.44) ($0.77)
Weighted Average Diluted Shares Outstanding		 132.75M 131.86M 132.57M 133.93M 131.67M 126.30M 126.85M 130.85M 130.25M 127.80M 128.67M
Weighted Average Basic & Diluted Shares Outstanding		 131.96M 132.57M 132.58M 132.58M 126.83M 126.85M 126.86M 126.91M 128.64M 128.67M 128.67M

Annual Cash Flow Statements for Organogenesis

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.66 0.50 19 39 24 30 -11 1.05 32 -42
Net Cash From Operating Activities		 -4.87 -3.49 -61 -34 5.47 62 25 31 14 -10
Net Cash From Continuing Operating Activities		 -4.87 -3.49 -61 -34 5.47 62 25 31 14 -10
Net Income / (Loss) Continuing Operations		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Consolidated Net Income / (Loss)		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Depreciation Expense		 5.70 3.59 3.31 3.78 4.44 5.78 5.85 10 14 15
Amortization Expense		 1.62 2.04 3.67 6.04 3.75 11 12 4.92 3.40 3.32
Non-Cash Adjustments To Reconcile Net Income		 12 9.79 0.67 4.72 7.49 23 16 18 42 48
Changes in Operating Assets and Liabilities, net		 -9.74 -11 -3.45 -9.37 -27 -71 -25 -7.62 -46 -114
Net Cash From Investing Activities		 -1.25 -15 -1.86 -6.23 -23 -31 -34 -24 -10 -14
Net Cash From Continuing Investing Activities		 -1.25 -15 -1.86 -6.23 -23 -31 -34 -24 -10 -14
Purchase of Property, Plant & Equipment		 -1.36 -2.43 -1.86 -5.98 -18 -31 -34 -24 -10 -14
Net Cash From Financing Activities		 6.78 19 82 79 42 -1.04 -2.20 -5.51 28 -17
Net Cash From Continuing Financing Activities		 6.78 19 82 79 42 -1.04 -2.20 -5.51 28 -17
Repayment of Debt		 -7.65 -8.60 -23 -19 -16 -65 -3.01 -5.17 -68 -1.17
Repurchase of Common Equity		 - - -0.27 -2.97 -5.66 0.00 0.00 0.00 -25 0.00
Issuance of Preferred Equity		 - - - - - - 0.00 0.00 121 0.00
Other Financing Activities, net		 17 -2.28 -11 -5.87 -0.69 0.98 0.81 -0.33 0.07 -16
Cash Interest Paid		 3.97 6.08 5.42 8.15 9.61 5.79 2.65 5.44 4.97 0.00
Cash Income Taxes Paid		 0.03 0.10 0.01 0.05 0.06 0.61 1.20 3.05 6.97 5.35

Quarterly Cash Flow Statements for Organogenesis

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 5.51 -15 1.13 4.45 41 -26 -37 -9.36 30 -2.23 -45
Net Cash From Operating Activities		 11 -10 4.74 8.70 11 -20 -33 3.08 39 21 -32
Net Cash From Continuing Operating Activities		 11 -10 4.74 8.70 11 -20 -33 3.08 39 21 -32
Net Income / (Loss) Continuing Operations		 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53 -96
Consolidated Net Income / (Loss)		 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53 -96
Depreciation Expense		 2.98 3.07 3.37 3.57 3.62 3.44 3.73 4.03 4.07 4.17 3.67
Amortization Expense		 1.23 0.90 0.83 0.83 0.83 0.84 0.84 0.84 0.80 5.71 0.43
Non-Cash Adjustments To Reconcile Net Income		 5.45 6.47 27 4.66 3.61 15 8.98 8.20 17 9.25 7.09
Changes in Operating Assets and Liabilities, net		 1.52 -19 -9.54 -13 -4.80 -20 -37 -32 -26 55 53
Net Cash From Investing Activities		 -3.32 -2.22 -1.88 -2.57 -3.36 -3.63 -3.64 -2.24 -4.65 -3.15 -1.10
Net Cash From Continuing Investing Activities		 -3.32 -2.22 -1.88 -2.57 -3.36 -3.63 -3.64 -2.24 -4.65 -3.15 -1.10
Purchase of Property, Plant & Equipment		 -3.32 -2.22 -1.88 -2.57 -3.36 -3.63 -3.64 -2.24 -4.65 -3.15 -1.10
Net Cash From Financing Activities		 -1.78 -2.61 -1.73 -1.68 34 -2.06 -0.29 -10 -4.81 -20 -13
Net Cash From Continuing Financing Activities		 -1.78 -2.61 -1.73 -1.68 34 -2.06 -0.29 -10 -4.81 -20 -13
Repayment of Debt		 -1.78 -1.67 -1.67 -1.68 -63 -0.29 -0.29 -0.30 -0.30 -9.84 -0.35
Other Financing Activities, net		 0.00 -0.94 -0.05 0.01 1.06 -1.77 - -9.91 -4.51 -10 -12

Annual Balance Sheets for Organogenesis

This table presents Organogenesis' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.42 311 149 164 221 290 443 449 460 498 599
Total Current Assets		 0.13 1.44 50 71 126 174 227 223 225 286 362
Cash & Equivalents		 0.13 1.04 2.31 21 60 84 114 102 104 136 94
Restricted Cash		 - - 0.05 0.11 0.20 0.41 0.60 0.81 0.50 0.58 0.65
Accounts Receivable		 - - 28 34 39 57 82 89 82 110 217
Inventories, net		 - - 14 13 23 28 25 25 28 26 30
Prepaid Expenses		 0.00 0.40 4.40 2.33 2.95 4.94 4.97 5.09 10 14 18
Other Current Assets		 - - 0.59 - - - - - - 0.00 2.43
Plant, Property, & Equipment, net		 0.00 0.00 42 40 47 56 79 102 116 89 104
Total Noncurrent Assets		 0.29 310 57 53 48 60 137 124 119 123 133
Goodwill		 - - 26 26 26 29 29 29 29 29 29
Intangible Assets		 - - 30 26 21 31 26 21 16 12 9.15
Noncurrent Deferred & Refundable Income Taxes		 - - 0.42 0.24 0.13 0.02 32 30 28 39 30
Other Noncurrent Operating Assets		 0.29 - 0.74 0.58 0.88 0.67 51 45 46 42 65
Total Liabilities & Shareholders' Equity		 0.42 311 149 164 221 290 443 449 460 498 599
Total Liabilities		 0.42 11 157 117 165 148 202 184 181 113 165
Total Current Liabilities		 0.42 0.48 52 56 60 68 83 75 81 77 100
Short-Term Debt		 - - 10 9.78 3.06 17 14 4.54 19 0.00 4.95
Accounts Payable		 - - 19 19 28 23 29 32 31 29 32
Accrued Expenses		 0.01 0.05 23 20 23 24 37 26 30 39 50
Other Current Liabilities		 0.41 0.43 - 6.76 5.00 4.20 1.64 12 1.08 9.11 14
Total Noncurrent Liabilities		 0.00 11 105 61 105 80 119 109 101 35 65
Long-Term Debt		 - - 85 39 83 53 71 66 61 0.00 0.00
Capital Lease Obligations		 - - 12 15 14 14 47 0.00 27 0.72 13
Other Noncurrent Operating Liabilities		 0.00 11 8.26 5.93 7.66 13 1.56 42 13 34 52
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 295 6.76 - - - - - 0.00 122 134
Total Equity & Noncontrolling Interests		 -0.00 5.00 -15 47 56 142 241 266 279 263 300
Total Preferred & Common Equity		 -0.00 5.00 -15 47 56 142 241 266 279 263 300
Preferred Stock		 0.00 0.00 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.00 5.00 -15 47 56 142 241 266 279 263 300
Common Stock		 0.03 5.23 50 177 227 297 302 311 320 303 303
Retained Earnings		 -0.03 -0.23 -65 -130 -171 -155 -61 -45 -41 -40 -3.08

Quarterly Balance Sheets for Organogenesis

This table presents Organogenesis' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 446 450 463 458 443 446 467 461 510 520 406
Total Current Assets		 217 216 226 227 234 239 268 260 300 269 200
Cash & Equivalents		 89 89 98 89 90 94 110 73 64 91 46
Restricted Cash		 0.72 0.59 0.60 0.72 0.58 0.59 0.57 0.66 0.63 0.72 0.75
Accounts Receivable		 92 94 89 96 106 101 103 120 169 117 101
Inventories, net		 26 25 28 28 27 27 29 33 40 28 29
Prepaid Expenses		 9.85 7.95 9.57 14 11 15 18 28 23 29 20
Other Current Assets		 - - - - - - 7.03 5.29 4.37 2.43 3.61
Plant, Property, & Equipment, net		 107 112 118 114 90 90 76 76 78 104 102
Total Noncurrent Assets		 123 122 120 117 119 118 124 125 132 147 105
Goodwill		 29 29 29 29 29 29 29 29 29 29 29
Intangible Assets		 20 18 17 15 14 13 12 11 9.94 3.44 3.00
Noncurrent Deferred & Refundable Income Taxes		 30 30 30 28 34 36 41 42 46 45 0.00
Other Noncurrent Operating Assets		 44 45 44 45 42 40 43 44 48 70 73
Total Liabilities & Shareholders' Equity		 446 450 463 458 443 446 467 461 510 520 406
Total Liabilities		 182 179 186 180 180 168 99 100 124 139 118
Total Current Liabilities		 76 73 81 83 86 77 65 66 90 76 57
Short-Term Debt		 17 18 5.48 5.49 17 16 8.07 4.80 8.58 4.76 0.00
Accounts Payable		 30 27 27 23 29 24 25 30 40 29 29
Accrued Expenses		 29 28 35 40 38 36 31 26 40 38 18
Other Current Liabilities		 0.00 0.21 14 14 1.13 1.15 1.19 4.97 1.21 4.96 9.31
Total Noncurrent Liabilities		 106 106 104 98 94 90 34 34 34 63 61
Long-Term Debt		 65 63 62 59 58 56 - 0.00 0.00 - 0.00
Capital Lease Obligations		 40 41 2.17 1.60 25 24 26 0.10 26 12 11
Other Noncurrent Operating Liabilities		 1.15 1.19 40 37 11 11 8.24 34 7.93 50 51
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - 125 128 131 137 140
Total Equity & Noncontrolling Interests		 264 271 277 278 264 279 243 233 255 245 148
Total Preferred & Common Equity		 264 271 277 278 264 279 243 233 255 245 148
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 264 271 277 278 264 279 243 233 255 245 148
Common Stock		 313 315 317 321 324 326 302 302 302 301 301
Retained Earnings		 -49 -44 -40 -43 -60 -48 -59 -68 -47 -56 -153

Annual Metrics And Ratios for Organogenesis

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 43.09% -2.55% 34.91% 29.63% 38.15% -3.52% -3.94% 11.29% 17.04%
EBITDA Growth		 0.00% 52.20% -4,821.60% 60.18% 308.26% 138.76% -54.63% -30.69% -43.60% 301.48%
EBIT Growth		 0.00% 29.12% -693.01% 46.59% 204.84% 148.61% -69.13% -43.56% -110.04% 3,638.32%
NOPAT Growth		 0.00% 37.39% -838.41% 42.09% 223.95% 316.31% -84.16% -65.11% -115.07% 4,023.57%
Net Income Growth		 0.00% 49.04% -761.54% 40.29% 144.52% 446.61% -83.51% -68.16% -82.59% 4,201.05%
EPS Growth		 0.00% 48.15% -571.43% 55.32% 135.71% 366.67% -82.86% -66.67% -125.00% 1,600.00%
Operating Cash Flow Growth		 0.00% 28.29% -1,635.90% 44.71% 116.30% 1,033.88% -59.89% 24.37% -54.04% -172.56%
Free Cash Flow Firm Growth		 0.00% 0.00% 73.41% 9.28% 30.10% 43.44% 504.07% -196.94% 171.89% -325.23%
Invested Capital Growth		 0.00% 981.97% -6.77% 6.59% 46.60% 84.32% -9.95% 20.37% -10.96% 41.02%
Revenue Q/Q Growth		 0.00% 0.00% -41.09% 4.42% 10.51% 4.72% -2.66% -3.53% 5.93% 21.27%
EBITDA Q/Q Growth		 0.00% 0.00% 8.91% 23.93% 127.77% 1.07% -12.63% -36.05% 30.03% 541.12%
EBIT Q/Q Growth		 0.00% 0.00% -5.25% 13.96% 272.63% -2.04% -33.13% -44.11% 90.09% 637.77%
NOPAT Q/Q Growth		 0.00% 0.00% -4.63% 7.24% 1,015.95% 49.63% -73.60% -57.35% 89.95% 701.00%
Net Income Q/Q Growth		 0.00% 0.00% -5.41% 14.57% 610.33% 54.01% -73.69% -61.96% 111.67% 3,584.78%
EPS Q/Q Growth		 0.00% 0.00% -46.88% 16.00% 475.00% 45.83% -73.33% -60.00% 83.33% 236.36%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -31.16% 24.71% 122.63% -7.83% -28.99% 10.01% 2.33% 73.42%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 79.55% 58.80% -123.19% 202.81% -198.38% 173.23% 18.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 785.42% 0.34% -1.99% 52.60% -15.54% 13.25% -10.64% -0.96%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 65.26% 69.16% 64.43% 70.90% 74.19% 75.57% 76.71% 75.42% 75.99% 75.62%
EBITDA Margin		 -1.38% -0.46% -23.20% -6.85% 11.00% 19.02% 8.94% 6.45% 3.27% 11.22%
Operating Margin		 -6.33% -2.77% -26.65% -11.44% 7.89% 15.45% 4.95% 2.89% -0.27% 7.92%
EBIT Margin		 -6.65% -3.29% -26.81% -10.61% 8.59% 15.45% 4.94% 2.90% -0.26% 7.92%
Profit (Net Income) Margin		 -10.64% -3.79% -33.51% -14.83% 5.09% 20.16% 3.44% 1.14% 0.18% 6.56%
Tax Burden Percent		 100.44% 51.72% 100.13% 100.39% 97.02% 149.32% 76.58% 47.58% -30.67% 78.84%
Interest Burden Percent		 159.33% 222.48% 124.84% 139.20% 61.16% 87.37% 90.99% 82.59% 222.25% 105.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 2.98% -49.32% 23.42% 52.42% 0.00% 21.16%
Return on Invested Capital (ROIC)		 0.00% -9.00% -38.74% -22.51% 21.93% 54.00% 6.94% 2.32% -0.34% 11.70%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -5.43% -77.62% -65.38% -22.65% -113.97% 27.66% 8.97% -2.97% 10.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 3.84% -298.17% -52.93% -4.46% -4.83% -0.82% -0.50% 0.60% -2.66%
Return on Equity (ROE)		 -9.84% -5.16% -336.91% -75.44% 17.46% 49.17% 6.13% 1.82% 0.26% 9.04%
Cash Return on Invested Capital (CROIC)		 0.00% -115.33% -31.74% -28.88% -15.87% -5.31% 17.41% -16.17% 11.26% -22.33%
Operating Return on Assets (OROA)		 -5.92% -2.84% -33.20% -14.41% 11.37% 19.69% 4.99% 2.77% -0.26% 8.15%
Return on Assets (ROA)		 -9.47% -3.27% -41.51% -20.14% 6.75% 25.69% 3.48% 1.09% 0.18% 6.75%
Return on Common Equity (ROCE)		 -0.16% 0.18% -277.71% -75.44% 17.46% 49.17% 6.13% 1.82% 0.21% 6.21%
Return on Equity Simple (ROE_SIMPLE)		 -295.32% 49.13% -137.82% -69.64% 12.15% 39.03% 5.85% 1.77% 0.33% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.14 -3.85 -36 -21 26 108 17 5.96 -0.90 35
NOPAT Margin		 -4.43% -1.94% -18.66% -8.01% 7.66% 23.07% 3.79% 1.38% -0.19% 6.25%
Net Nonoperating Expense Percent (NNEP)		 -2.77% -3.57% 38.88% 42.87% 44.58% 167.97% -20.72% -6.65% 2.64% 1.65%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - 5.08% 1.55% -0.34% 11.26%
Cost of Revenue to Revenue		 34.74% 30.84% 35.57% 29.10% 25.81% 24.44% 23.29% 24.58% 24.01% 24.38%
SG&A Expenses to Revenue		 67.06% 67.36% 83.72% 76.67% 60.36% 53.53% 62.94% 62.28% 61.10% 57.83%
R&D to Revenue		 4.52% 4.57% 5.55% 5.67% 5.94% 6.58% 8.82% 10.25% 10.43% 7.90%
Operating Expenses to Revenue		 71.58% 71.93% 91.08% 82.34% 66.30% 60.11% 71.76% 72.52% 76.26% 67.70%
Earnings before Interest and Taxes (EBIT)		 -9.23 -6.54 -52 -28 29 72 22 13 -1.26 45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.91 -0.91 -45 -18 37 89 40 28 16 63
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.25 8.20 5.72 4.93 1.33 1.94 1.61 2.19
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 49.28 9.85 6.36 1.63 2.31 1.91 2.51
Price to Revenue (P/Rev)		 0.00 1.94 0.31 1.75 2.40 2.54 0.78 1.25 0.88 1.17
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 12.62 22.67 109.21 0.00 32.83
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 7.93% 4.41% 0.92% 0.00% 3.05%
Enterprise Value to Invested Capital (EV/IC)		 0.00 5.15 1.13 5.18 5.77 4.66 1.37 1.93 1.65 2.01
Enterprise Value to Revenue (EV/Rev)		 0.00 2.50 0.53 1.90 2.40 2.58 0.71 1.25 0.85 1.26
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 21.77 13.57 7.93 19.39 26.09 11.21
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 27.90 16.71 14.34 43.08 0.00 15.88
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 31.28 11.19 18.71 90.94 0.00 20.14
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 148.24 19.46 12.86 17.53 28.94 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 7.46 0.00 13.77 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 -12.55 1.37 1.81 0.59 0.55 0.27 0.38 0.00 0.03
Long-Term Debt to Equity		 0.00 -11.33 1.16 1.76 0.47 0.49 0.25 0.31 0.00 0.03
Financial Leverage		 -1.04 -0.71 3.84 0.81 0.20 0.04 -0.03 -0.06 -0.20 -0.26
Leverage Ratio		 1.04 1.58 8.12 3.75 2.59 1.91 1.76 1.67 1.44 1.34
Compound Leverage Factor		 1.66 3.51 10.13 5.21 1.58 1.67 1.60 1.38 3.21 1.41
Debt to Total Capital		 0.00% 108.66% 57.74% 64.41% 37.05% 35.37% 21.03% 27.62% 0.19% 2.86%
Short-Term Debt to Total Capital		 0.00% 10.50% 8.79% 1.96% 7.40% 3.87% 1.35% 4.84% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 98.16% 48.95% 62.46% 29.65% 31.51% 19.69% 22.78% 0.19% 2.86%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 98.33% 6.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.71% 29.95%
Common Equity to Total Capital		 1.67% -15.51% 42.26% 35.59% 62.95% 64.63% 78.97% 72.38% 68.10% 67.19%
Debt to EBITDA		 0.00 -117.69 -1.43 -5.63 2.24 1.49 1.76 3.80 0.05 0.20
Net Debt to EBITDA		 0.00 -115.11 -0.95 -2.25 -0.04 0.20 -0.81 0.07 -8.59 -1.29
Long-Term Debt to EBITDA		 0.00 -106.32 -1.21 -5.46 1.79 1.32 1.64 3.14 0.05 0.20
Debt to NOPAT		 0.00 -27.91 -1.78 -4.81 3.22 1.23 4.14 17.84 -0.80 0.36
Net Debt to NOPAT		 0.00 -27.30 -1.19 -1.93 -0.05 0.16 -1.90 0.33 150.80 -2.31
Long-Term Debt to NOPAT		 0.00 -25.21 -1.51 -4.67 2.58 1.09 3.88 14.71 -0.80 0.36
Altman Z-Score		 0.00 2.02 -0.56 1.70 4.47 5.32 2.57 3.07 3.61 4.10
Noncontrolling Interest Sharing Ratio		 98.33% 103.54% 17.57% 0.00% 0.00% 0.00% 0.00% 0.00% 18.44% 31.27%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.00 0.96 1.27 2.10 2.56 2.74 2.97 2.80 3.69 3.62
Quick Ratio		 2.17 0.59 0.99 1.66 2.07 2.37 2.56 2.31 3.17 3.11
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -111 -30 -27 -19 -11 43 -42 30 -67
Operating Cash Flow to CapEx		 -390.93% -144.46% -3,266.97% -560.29% 30.92% 198.52% 73.33% 126.90% 141.63% -72.85%
Free Cash Flow to Firm to Interest Expense		 0.00 -13.88 -2.29 -2.47 -1.66 -1.16 21.33 -18.96 19.34 0.00
Operating Cash Flow to Interest Expense		 -0.87 -0.44 -4.71 -3.09 0.48 6.80 12.37 14.12 9.20 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1.09 -0.74 -4.85 -3.64 -1.08 3.37 -4.50 2.99 2.70 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.89 0.86 1.24 1.36 1.32 1.27 1.01 0.95 1.01 1.03
Accounts Receivable Turnover		 0.00 0.00 6.22 7.11 7.04 6.71 5.25 5.05 5.02 3.45
Inventory Turnover		 0.00 0.00 4.99 4.19 3.44 4.32 4.22 4.02 4.25 4.93
Fixed Asset Turnover		 0.00 0.00 4.73 6.01 6.57 6.93 4.97 3.96 4.69 5.85
Accounts Payable Turnover		 0.00 0.00 3.60 3.19 3.37 4.33 3.41 3.38 3.88 4.52
Days Sales Outstanding (DSO)		 0.00 0.00 58.68 51.35 51.88 54.38 69.58 72.24 72.64 105.88
Days Inventory Outstanding (DIO)		 0.00 0.00 73.18 87.08 106.00 84.41 86.55 90.90 85.89 74.11
Days Payable Outstanding (DPO)		 0.00 0.00 101.37 114.27 108.20 84.25 107.17 108.07 94.03 80.76
Cash Conversion Cycle (CCC)		 0.00 0.00 30.49 24.17 49.68 54.54 48.96 55.07 64.50 99.23
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -11 96 90 96 140 259 233 281 250 352
Invested Capital Turnover		 -12.69 4.64 2.08 2.81 2.86 2.34 1.83 1.69 1.82 1.87
Increase / (Decrease) in Invested Capital		 0.00 107 -6.53 5.92 45 118 -26 47 -31 102
Enterprise Value (EV)		 0.00 496 102 496 810 1,206 320 542 411 710
Market Capitalization		 0.00 384 59 456 812 1,189 352 540 424 657
Book Value per Share		 $0.13 ($0.40) $8.09 $0.59 $1.32 $1.88 $2.03 $2.11 $1.98 $2.36
Tangible Book Value per Share		 $0.13 ($1.82) ($0.79) $0.10 $0.76 $1.45 $1.65 $1.77 $1.67 $2.07
Total Capital		 300 99 111 156 225 373 336 385 386 447
Total Debt		 0.00 107 64 101 83 132 71 106 0.72 13
Total Long-Term Debt		 0.00 97 54 98 67 118 66 88 0.72 13
Net Debt		 -311 105 43 40 -1.34 18 -33 1.98 -135 -82
Capital Expenditures (CapEx)		 1.25 2.42 1.86 5.98 18 31 34 24 10 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 5.78 3.41 8.39 38 44 49 59 72 168
Debt-free Net Working Capital (DFNWC)		 0.96 8.14 25 69 123 159 152 163 208 262
Net Working Capital (NWC)		 0.96 -2.23 15 66 106 144 148 145 208 262
Net Nonoperating Expense (NNE)		 8.62 3.68 29 18 8.67 14 1.55 1.01 -1.76 -1.79
Net Nonoperating Obligations (NNO)		 -311 105 43 40 -1.34 18 -33 1.98 -135 -82
Total Depreciation and Amortization (D&A)		 7.32 5.63 6.98 9.83 8.18 17 18 15 17 19
Debt-free, Cash-free Net Working Capital to Revenue		 -0.06% 2.91% 1.76% 3.22% 11.23% 9.45% 10.83% 13.58% 15.00% 29.73%
Debt-free Net Working Capital to Revenue		 0.69% 4.10% 12.83% 26.35% 36.30% 33.96% 33.74% 37.67% 43.25% 46.45%
Net Working Capital to Revenue		 0.69% -1.12% 7.77% 25.18% 31.37% 30.87% 32.73% 33.37% 43.25% 46.45%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.03) ($0.48) ($0.94) ($0.44) $0.17 $0.74 $0.00 $0.04 ($0.01) $0.16
Adjusted Weighted Average Basic Shares Outstanding		 63.20M 38.75M 92.01M 105.36M 107.74M 128.33M 0.00 131.23M 131.67M 126.74M
Adjusted Diluted Earnings per Share		 ($0.03) ($0.48) ($0.94) ($0.44) $0.16 $0.71 $0.00 $0.04 ($0.01) $0.15
Adjusted Weighted Average Diluted Shares Outstanding		 63.20M 38.75M 92.01M 105.36M 111.36M 133.66M 0.00 132.75M 131.67M 130.25M
Adjusted Basic & Diluted Earnings per Share		 ($0.03) ($0.48) ($0.94) ($0.44) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.92M 9.33M 69.32M 92.84M 127.99M 128.77M 0.00 131.96M 126.83M 128.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.14 -3.85 -36 -21 26 51 17 8.77 12 44
Normalized NOPAT Margin		 -4.43% -1.94% -18.66% -8.01% 7.66% 10.82% 3.79% 2.02% 2.55% 7.81%
Pre Tax Income Margin		 -10.60% -7.33% -33.47% -14.77% 5.25% 13.50% 4.50% 2.40% -0.58% 8.33%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -1.64 -0.82 -4.03 -2.55 2.58 7.92 11.10 5.75 -0.82 0.00
NOPAT to Interest Expense		 -1.09 -0.48 -2.80 -1.92 2.30 11.83 8.50 2.72 -0.58 0.00
EBIT Less CapEx to Interest Expense		 -1.86 -1.12 -4.17 -3.10 1.01 4.49 -5.78 -5.38 -7.32 0.00
NOPAT Less CapEx to Interest Expense		 -1.31 -0.78 -2.95 -2.48 0.73 8.40 -8.37 -8.40 -7.08 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 -35.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -35.22% 0.00% -0.42% -7.68% 32.82% 0.00% 0.00% 0.00% 2,959.23% 0.00%

Quarterly Metrics And Ratios for Organogenesis

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 126,828,092.00 126,853,536.00 126,857,709.00 - 128,640,671.00 128,674,548.00
DEI Adjusted Shares Outstanding		 - - - - - 126,828,092.00 126,853,536.00 126,857,709.00 - 128,640,671.00 128,674,548.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -0.17 -0.10 0.11 - -0.44 -0.77
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -13.73% 2.17% 11.01% 6.12% 27.10% -21.17% -22.44% 30.98% 78.13% -57.06% -56.68%
EBITDA Growth		 -84.44% 366.67% -173.47% -9.75% 401.75% -15,695.83% 18.44% 139.45% 364.82% -162.58% -491.79%
EBIT Growth		 -114.84% 3.75% -242.43% -22.11% 887.64% -598.46% 10.18% 229.60% 520.01% -157.45% -308.05%
NOPAT Growth		 -111.92% 3.72% -272.30% 295.96% 960.92% -594.34% 9.47% 59.82% 470.18% -157.58% -305.47%
Net Income Growth		 -107.60% 29.27% -420.60% 289.36% 1,448.51% -797.29% 44.89% 74.90% 469.53% -182.10% -924.99%
EPS Growth		 0.00% 0.00% -425.00% 350.00% 0.00% -750.00% 23.08% 22.22% 520.00% -158.82% -670.00%
Operating Cash Flow Growth		 36.08% -100.16% -45.20% -48.04% 3.04% -96.17% -793.82% -64.59% 260.43% 205.98% 3.71%
Free Cash Flow Firm Growth		 -245.65% 212.06% 175.00% -158.95% 179.38% -242.31% -230.67% -195.59% -253.33% -14.03% 116.09%
Invested Capital Growth		 20.37% -13.99% -10.35% 12.85% -10.96% 14.30% 7.20% 27.23% 41.02% 5.05% -13.77%
Revenue Q/Q Growth		 -8.18% 10.36% 18.42% -11.56% 9.97% -31.55% 16.51% 49.36% 49.54% -83.50% 17.53%
EBITDA Q/Q Growth		 -75.38% -98.69% -6,850.00% 210.06% 36.86% -253.39% 64.70% 423.11% 165.67% -186.65% 20.44%
EBIT Q/Q Growth		 -116.01% -195.90% -263.54% 145.22% 61.93% -362.40% 53.25% 265.92% 204.61% -208.96% 25.90%
NOPAT Q/Q Growth		 -126.61% -203.55% -260.64% 235.93% -42.14% -344.81% 52.98% 339.98% 106.41% -210.59% 25.98%
Net Income Q/Q Growth		 -117.97% -269.07% -711.57% 172.35% -37.77% -345.58% 50.16% 329.63% 102.62% -221.64% -81.10%
EPS Q/Q Growth		 0.00% 0.00% -550.00% 169.23% -44.44% -440.00% 41.18% 210.00% 181.82% -241.94% -75.00%
Operating Cash Flow Q/Q Growth		 -36.57% -195.75% 146.62% 83.52% 25.78% -282.27% -64.90% 109.37% 1,180.29% -46.41% -249.82%
Free Cash Flow Firm Q/Q Growth		 -253.21% 360.11% -43.91% -185.55% 306.31% -243.76% 48.50% -93.52% -7.02% -6.91% 107.27%
Invested Capital Q/Q Growth		 13.25% 3.23% 6.90% 2.53% -10.64% 16.71% 0.25% 21.69% -0.96% -13.06% -17.71%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 72.13% 73.91% 77.58% 76.73% 75.48% 72.64% 72.64% 75.97% 77.87% 30.77% 45.90%
EBITDA Margin		 2.93% 0.13% -7.46% 9.29% 11.56% -25.91% -7.85% 16.98% 30.17% -158.41% -107.23%
Operating Margin		 -1.27% -3.50% -10.67% 5.42% 8.07% -30.85% -12.45% 13.74% 28.05% -185.05% -116.54%
EBIT Margin		 -1.30% -3.48% -10.69% 5.46% 8.05% -30.85% -12.38% 13.75% 28.01% -184.95% -116.60%
Profit (Net Income) Margin		 -0.57% -1.91% -13.09% 10.71% 6.06% -21.74% -9.30% 14.30% 19.37% -142.79% -220.01%
Tax Burden Percent		 31.66% 48.35% 117.21% 211.76% 74.84% 73.08% 79.36% 101.92% 68.90% 77.63% 189.20%
Interest Burden Percent		 138.87% 113.42% 104.45% 92.52% 100.60% 96.41% 94.65% 102.00% 100.37% 99.45% 99.73%
Effective Tax Rate		 0.00% 0.00% 0.00% -111.76% 25.16% 0.00% 0.00% -1.92% 31.10% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1.50% -3.87% -11.61% 19.80% 10.97% -36.24% -13.25% 20.50% 36.21% -222.98% -137.08%
ROIC Less NNEP Spread (ROIC-NNEP)		 -3.59% 7.99% -46.29% 26.15% 10.93% -36.00% -11.27% 17.47% 36.12% -216.47% -21.55%
Return on Net Nonoperating Assets (RNNOA)		 0.20% 0.15% -3.65% -1.32% -2.20% 5.53% 1.08% -0.76% -9.57% 43.73% 3.48%
Return on Equity (ROE)		 -1.30% -3.72% -15.26% 18.49% 8.77% -30.71% -12.17% 19.74% 26.64% -179.25% -133.60%
Cash Return on Invested Capital (CROIC)		 -16.17% 17.54% 8.25% -15.46% 11.26% -19.54% -12.61% -25.81% -22.33% -4.39% 5.57%
Operating Return on Assets (OROA)		 -1.24% -3.35% -10.73% 5.47% 8.10% -30.57% -11.76% 13.38% 28.82% -192.82% -122.96%
Return on Assets (ROA)		 -0.54% -1.84% -13.13% 10.72% 6.10% -21.54% -8.83% 13.91% 19.93% -148.86% -232.02%
Return on Common Equity (ROCE)		 -1.30% -3.72% -15.26% 18.49% 7.16% -24.76% -9.68% 15.85% 18.31% -116.59% -78.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 2.09% -6.28% -2.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.89 -2.70 -9.72 13 7.65 -19 -8.80 21 44 -48 -36
NOPAT Margin		 -0.89% -2.45% -7.47% 11.48% 6.04% -21.60% -8.72% 14.00% 19.33% -129.54% -81.58%
Net Nonoperating Expense Percent (NNEP)		 2.09% -11.86% 34.69% -6.35% 0.04% -0.24% -1.98% 3.03% 0.09% -6.52% -115.52%
Return On Investment Capital (ROIC_SIMPLE)		 -0.23% - - - 2.90% -6.76% -3.70% 7.30% 13.94% -18.43% -22.44%
Cost of Revenue to Revenue		 27.87% 26.09% 22.42% 23.27% 24.52% 27.36% 27.36% 24.03% 22.13% 69.23% 54.10%
SG&A Expenses to Revenue		 61.60% 65.76% 58.77% 62.33% 58.31% 83.64% 73.08% 52.86% 44.40% 175.10% 123.33%
R&D to Revenue		 11.81% 11.65% 11.97% 8.98% 9.10% 12.27% 10.29% 8.76% 4.56% 40.72% 41.82%
Operating Expenses to Revenue		 73.41% 77.41% 88.25% 71.32% 67.42% 103.49% 85.10% 62.23% 49.82% 215.82% 162.44%
Earnings before Interest and Taxes (EBIT)		 -1.29 -3.83 -14 6.29 10 -27 -13 21 63 -69 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.92 0.14 -9.72 11 15 -22 -7.93 26 68 -59 -47
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.94 1.35 1.41 1.36 1.61 2.26 1.99 2.10 2.19 1.25 2.11
Price to Tangible Book Value (P/TBV)		 2.31 1.60 1.68 1.60 1.91 2.71 2.40 2.47 2.51 1.44 2.68
Price to Revenue (P/Rev)		 1.25 0.86 0.83 0.83 0.88 1.19 1.08 1.15 1.17 0.59 0.68
Price to Earnings (P/E)		 109.21 64.46 0.00 0.00 0.00 0.00 0.00 0.00 32.83 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.92% 1.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.05% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.93 1.38 1.39 1.36 1.65 2.05 1.79 1.79 2.01 1.20 1.65
Enterprise Value to Revenue (EV/Rev)		 1.25 0.81 0.85 0.84 0.85 1.30 1.22 1.37 1.26 0.71 0.91
Enterprise Value to EBITDA (EV/EBITDA)		 19.39 9.71 28.65 31.37 26.09 0.00 0.00 64.43 11.21 13.70 0.00
Enterprise Value to EBIT (EV/EBIT)		 43.08 27.64 0.00 0.00 0.00 0.00 0.00 0.00 15.88 142.13 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 90.94 50.98 0.00 0.00 0.00 0.00 0.00 0.00 20.14 226.45 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 17.53 13.62 17.35 27.39 28.94 134.53 0.00 0.00 0.00 11.92 13.03
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 7.27 15.98 0.00 13.77 0.00 0.00 0.00 0.00 0.00 27.47
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.38 0.24 0.38 0.34 0.00 0.09 0.01 0.09 0.03 0.04 0.04
Long-Term Debt to Equity		 0.31 0.22 0.31 0.29 0.00 0.07 0.00 0.07 0.03 0.03 0.04
Financial Leverage		 -0.06 0.02 0.08 -0.05 -0.20 -0.15 -0.10 -0.04 -0.26 -0.20 -0.16
Leverage Ratio		 1.67 1.67 1.67 1.64 1.44 1.43 1.45 1.44 1.34 1.32 1.34
Compound Leverage Factor		 2.32 1.89 1.75 1.51 1.45 1.38 1.37 1.47 1.34 1.31 1.33
Debt to Total Capital		 27.62% 19.29% 27.46% 25.63% 0.19% 8.48% 1.34% 8.14% 2.86% 4.30% 3.62%
Short-Term Debt to Total Capital		 4.84% 1.59% 4.73% 4.29% 0.00% 2.01% 1.31% 2.04% 0.00% 1.20% 0.00%
Long-Term Debt to Total Capital		 22.78% 17.70% 22.72% 21.35% 0.19% 6.47% 0.03% 6.09% 2.86% 3.10% 3.62%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 31.71% 31.12% 34.96% 31.14% 29.95% 34.33% 46.78%
Common Equity to Total Capital		 72.38% 80.71% 72.54% 74.37% 68.10% 60.40% 63.71% 60.72% 67.19% 61.37% 49.60%
Debt to EBITDA		 3.80 1.83 7.51 7.92 0.05 -4.99 -0.97 3.46 0.20 0.64 -0.89
Net Debt to EBITDA		 0.07 -0.63 0.70 0.09 -8.59 11.18 13.64 -3.06 -1.29 -2.80 2.95
Long-Term Debt to EBITDA		 3.14 1.68 6.21 6.60 0.05 -3.81 -0.02 2.59 0.20 0.46 -0.89
Debt to NOPAT		 17.84 9.63 -12.99 -10.74 -0.80 -2.02 -0.31 -5.83 0.36 10.57 -0.43
Net Debt to NOPAT		 0.33 -3.32 -1.21 -0.12 150.80 4.52 4.30 5.15 -2.31 -46.30 1.43
Long-Term Debt to NOPAT		 14.71 8.83 -10.75 -8.94 -0.80 -1.54 -0.01 -4.37 0.36 7.63 -0.43
Altman Z-Score		 2.97 2.41 2.36 2.71 3.69 4.45 3.93 4.00 4.20 2.17 2.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 18.44% 19.37% 20.49% 19.69% 31.27% 34.96% 41.25%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.80 2.74 2.73 3.09 3.69 4.12 3.95 3.32 3.62 3.53 3.52
Quick Ratio		 2.31 2.23 2.28 2.53 3.17 3.28 2.94 2.57 3.11 2.74 2.58
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -48 39 22 -19 38 -55 -28 -55 -59 -63 4.58
Operating Cash Flow to CapEx		 319.31% -457.34% 252.02% 338.46% 325.41% -549.78% -903.60% 137.76% 847.38% 671.55% -2,877.55%
Free Cash Flow to Firm to Interest Expense		 -96.19 75.48 35.10 -39.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 21.10 -19.77 7.64 18.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 14.49 -24.09 4.61 13.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.95 0.96 1.00 1.00 1.01 0.99 0.95 0.97 1.03 1.04 1.05
Accounts Receivable Turnover		 5.05 4.63 4.49 4.78 5.02 4.60 3.80 3.45 3.45 4.67 4.13
Inventory Turnover		 4.02 4.08 4.27 4.09 4.25 3.88 3.64 3.56 4.93 4.83 4.35
Fixed Asset Turnover		 3.96 3.94 4.44 4.39 4.69 4.84 5.19 5.54 5.85 5.73 5.16
Accounts Payable Turnover		 3.38 4.06 3.93 4.43 3.88 4.63 3.69 3.70 4.52 5.24 4.60
Days Sales Outstanding (DSO)		 72.24 78.86 81.22 76.42 72.64 79.35 96.16 105.94 105.88 78.09 88.29
Days Inventory Outstanding (DIO)		 90.90 89.48 85.55 89.16 85.89 93.97 100.15 102.46 74.11 75.53 83.87
Days Payable Outstanding (DPO)		 108.07 90.00 92.98 82.37 94.03 78.90 98.79 98.73 80.76 69.66 79.42
Cash Conversion Cycle (CCC)		 55.07 78.34 73.80 83.22 64.50 94.41 97.52 109.68 99.23 83.96 92.75
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 281 255 273 280 250 292 292 356 352 306 252
Invested Capital Turnover		 1.69 1.58 1.55 1.73 1.82 1.68 1.52 1.46 1.87 1.72 1.68
Increase / (Decrease) in Invested Capital		 47 -41 -31 32 -31 36 20 76 102 15 -40
Enterprise Value (EV)		 542 352 380 380 411 597 523 636 710 367 417
Market Capitalization		 540 375 371 379 424 548 464 535 657 305 313
Book Value per Share		 $2.11 $2.11 $1.99 $2.10 $1.98 $1.92 $1.84 $2.01 $2.36 $1.90 $1.15
Tangible Book Value per Share		 $1.77 $1.78 $1.66 $1.78 $1.67 $1.60 $1.53 $1.71 $2.07 $1.65 $0.91
Total Capital		 385 344 363 375 386 402 366 420 447 398 299
Total Debt		 106 66 100 96 0.72 34 4.89 34 13 17 11
Total Long-Term Debt		 88 61 83 80 0.72 26 0.10 26 13 12 11
Net Debt		 1.98 -23 9.25 1.09 -135 -76 -69 -30 -82 -75 -36
Capital Expenditures (CapEx)		 3.32 2.22 1.88 2.57 3.36 3.63 3.64 2.24 4.65 3.15 1.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 59 61 75 82 72 101 125 154 168 105 96
Debt-free Net Working Capital (DFNWC)		 163 150 166 177 208 211 199 218 262 197 143
Net Working Capital (NWC)		 145 144 148 161 208 203 194 209 262 192 143
Net Nonoperating Expense (NNE)		 -0.32 -0.60 7.32 0.89 -0.03 0.12 0.59 -0.44 -0.10 4.93 61
Net Nonoperating Obligations (NNO)		 1.98 -23 9.25 1.09 -135 -76 -69 -30 -82 -75 -36
Total Depreciation and Amortization (D&A)		 4.21 3.97 4.20 4.40 4.45 4.29 4.58 4.87 4.86 9.88 4.10
Debt-free, Cash-free Net Working Capital to Revenue		 13.58% 13.90% 16.77% 18.10% 15.00% 21.94% 29.21% 33.03% 29.73% 20.43% 21.09%
Debt-free Net Working Capital to Revenue		 37.67% 34.41% 36.95% 38.96% 43.25% 46.03% 46.37% 46.86% 46.45% 38.32% 31.33%
Net Working Capital to Revenue		 33.37% 33.15% 33.11% 35.43% 43.25% 44.27% 45.25% 45.02% 46.45% 37.40% 31.33%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.32 ($0.44) ($0.77)
Adjusted Weighted Average Basic Shares Outstanding		 131.23M 131.86M 132.57M 132.58M 131.67M 126.30M 126.85M 126.88M 126.74M 127.80M 128.67M
Adjusted Diluted Earnings per Share		 $0.00 ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.31 ($0.44) ($0.77)
Adjusted Weighted Average Diluted Shares Outstanding		 132.75M 131.86M 132.57M 133.93M 131.67M 126.30M 126.85M 130.85M 130.25M 127.80M 128.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 131.96M 132.57M 132.58M 132.58M 126.83M 126.85M 126.86M 126.91M 128.64M 128.67M 128.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.89 -2.70 3.47 4.37 7.65 -14 -7.58 15 45 -48 -36
Normalized NOPAT Margin		 -0.89% -2.45% 2.66% 3.79% 6.04% -16.29% -7.51% 10.05% 19.92% -129.54% -81.58%
Pre Tax Income Margin		 -1.80% -3.95% -11.16% 5.06% 8.10% -29.74% -11.72% 14.03% 28.11% -183.93% -116.28%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2.57 -7.45 -22.45 13.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -1.77 -5.25 -15.68 28.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -9.18 -11.77 -25.48 7.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -8.37 -9.57 -18.72 22.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 2,959.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Organogenesis Holdings (NASDAQ: ORGO) is showing a mixed financial picture, with some sequential improvement in profitability but significant deterioration in revenue, cash flow and liquidity compared with the prior year. The latest quarter also includes a large income-tax expense despite a pretax loss, making reported net income particularly weak.

  • Sequential revenue and gross profit improved. Second-quarter 2026 revenue rose to $43.8 million from $37.2 million in the first quarter, while gross profit increased to $20.1 million from $11.5 million. Gross margin also improved to approximately 45.9% from 30.8% sequentially.
  • The operating loss narrowed from the first quarter. Operating loss improved to $51.0 million in Q2 2026 from $68.9 million in Q1, helped by lower selling, general and administrative costs and the absence of the first quarter’s $45.3 million deferred-tax asset balance.
  • Debt levels remain limited. Organogenesis reported no short-term or long-term debt at June 30, 2026. Capital lease obligations totaled $10.8 million, down from $12.4 million in the first quarter and $25.6 million in Q3 2025.
  • Working-capital liquidity remains substantial on the balance sheet. Current assets of $200.3 million exceeded current liabilities of $57.0 million by a wide margin, implying a current ratio of roughly 3.5.
  • Operating-asset changes supported cash flow, but the quality of that support is uncertain. Changes in operating assets and liabilities provided $53.4 million in Q2 2026, nearly offsetting the company’s $96.3 million net loss. Investors should monitor whether this benefit is recurring or reflects temporary working-capital movements.
  • Research and development spending remains elevated. R&D expense increased to $18.3 million in Q2 2026 from $15.2 million in Q1 and $10.4 million in Q2 2025. This spending could support future products, but it is currently contributing to operating losses.
  • Revenue has fallen sharply year over year. Q2 2026 revenue of $43.8 million was down approximately 57% from $101.0 million in Q2 2025, 66% from $130.2 million in Q2 2024 and 63% from $117.3 million in Q2 2023. The latest results suggest a major contraction in the company’s revenue base.
  • Gross-margin performance remains well below earlier periods. Q2 2026 gross margin was approximately 45.9%, compared with 72.6% in Q2 2025, 77.6% in Q2 2024 and 77.6% in Q2 2023. Lower margins make it more difficult for revenue to cover operating expenses.
  • Cash flow deteriorated materially. Operating cash flow was negative $31.7 million in Q2 2026, compared with positive operating cash flow of $21.1 million in Q1 2026 and negative $32.9 million in Q2 2025. Including investing and financing activity, cash declined by $45.3 million during the quarter.
  • The cash balance is declining rapidly. Cash and equivalents fell to $46.1 million at June 30, 2026, from $91.4 million at March 31 and $73.1 million at June 30, 2025. Although the current ratio remains strong, continued quarterly cash burn could pressure the company to reduce spending, raise capital or pursue additional financing.

Organogenesis reported a net loss of $96.3 million in Q2 2026, or $0.77 per diluted share, compared with a $53.2 million loss in Q1. A $45.4 million income-tax expense was recorded despite a pretax loss of $50.9 million, which significantly amplified the reported net loss and warrants additional review in the company’s filings.

The balance sheet also shows a growing retained deficit, which reached $152.5 million at the end of Q2 from $56.2 million in Q1. Redeemable noncontrolling interest stood at $139.9 million, a sizable claim alongside the company’s common equity. Overall, Organogenesis retains meaningful current assets and limited conventional debt, but the combination of collapsing comparable-quarter revenue, weak margins, recurring losses and rapid cash depletion represents a substantial risk for investors.

10/14/26 07:33 AM ETAI Generated. May Contain Errors.

Organogenesis Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Organogenesis' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Organogenesis' net income appears to be on an upward trend, with a most recent value of $37.03 million in 2025, compared with -$14.77 million in 2016. The previous period was $861 thousand in 2024. Check out Organogenesis' forecast to explore projected trends and price targets.

Organogenesis' total operating income in 2025 was $44.69 million, based on the following breakdown:
  • Total Gross Profit: $426.65 million
  • Total Operating Expenses: $381.95 million

Over the last 9 years, Organogenesis' total revenue changed from $138.73 million in 2016 to $564.17 million in 2025, a change of 306.7%.

In the past 13 quarters, Organogenesis' cash and equivalents has ranged from $46.10 million in Q2 2026 to $109.97 million in Q1 2025, and is currently $46.10 million as of their latest financial filing in Q2 2026.

Organogenesis had total debt of $12.79 million at the end of 2025, a 1,681.1% increase from 2024, and none in 2016.

Over the last 9 years, Organogenesis' book value per share changed from 0.13 in 2016 to 2.36 in 2025, a change of 1,727.6%.


Related Companies

Financial statements for NASDAQ:ORGO last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
This AI fund posted a 34 percent annualized payout last month
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...
Decentralized Masters | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel